Testing if lab drug screening can predict cancer treatment responses

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The EVIDENT study aims to evaluate whether ex vivo drug screening can accurately predict the response of patients with solid tumors to standard cancer treatments. Eligible participants will provide fresh tumor samples during surgery, biopsy, or fluid aspiration, which will then be tested against various therapies, including both standard and novel treatments. The study will compare the results of these screenings with the actual clinical outcomes of the patients' treatments to assess the predictive accuracy of the screening method. This feasibility study will initially focus on bladder cancer, kidney cancer, melanoma, sarcoma, and glioblastoma, with potential to expand to other solid tumors in the future.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\>16 years of age with a diagnosis of known or suspected solid cancer who will undergo surgery, biopsy, aspirate, or TURBT

Willing to donate a section fresh tumour tissue from surgery, a TURBT, fluid aspirate, or biopsy surplus to diagnostic use

Willing to donate a 9ml blood sample

Able to give written informed consent

Previously treated patients are eligible if:

* Present with a recurrence of a previously treated tumour. This may be a local or metastatic recurrence
* Have undergone treatment for their cancer, but fail to respond to this and progress
* Have received neoadjuvant therapy for their tumour
* Have undergone chemotherapy, targeted therapy, immunotherapy, hormone therapy and or radiotherapy for a previous tumour

Exclusion Criteria:

Patients with a known diagnosis of a blood borne virus (Hepatitis B, Hepatitis C, HIV). (The laboratories where experiments will be conducted do not have the safety facilities to use material containing these pathogens)

Patients with a current positive COVID-19 infection

Where it's running

• Sheffield Teaching Hospitals NHS Foundation Trust
  Sheffield, South Yorkshire, United Kingdom Recruiting

Study contacts

• Principal investigator: Sarah Danson, PhD, FRCP — University of Sheffield, Sheffield Teaching Hospitals NHS Foundation Trust
• Study coordinator: Greg Wells, PhD
• Email: g.wells@sheffield.ac.uk
• Phone: +44 114 215 9098

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• EBNK-001 allogeneic NK cell therapy with low-dose IL-15, with or without pembrolizumab, for advanced solid tumors

  This treatment tests an off-the-shelf NK cell product (EBNK-001) given with low-dose IL-15, either alone or with pembrolizumab, in adults with advanced or metastatic solid tumors who have exhausted standard options.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410676

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues

  This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06580002

• Using stereotactic body radiotherapy for patients with rare oligometastatic cancers

  This study is testing if adding a special type of targeted radiation therapy to standard treatment can help people with rare cancers that have spread to a few places live longer and feel better.

  Recruiting at 13 sites European Organisation for Research and Treatment of Cancer - EORTC · Anderlecht and 12 other locations · NCT04498767

• Evaluating progastrin levels in cancer patients

  This study is testing if measuring progastrin levels in the blood can help predict how cancer will progress and respond to treatment in patients with different types of cancer.

  Recruiting at 17 sites Hospices Civils de Lyon · Bron and 16 other locations · NCT03787056

• A resource for collecting cancer data and biospecimens

  This study is creating a resource to collect health information and samples from cancer patients and healthy individuals to help improve cancer prevention and treatment strategies.

  Recruiting at 42 sites University of Nebraska · Greenwood Village, Colorado and 41 other locations · NCT02012699

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.